Life sciences is among a select group of highly innovative industries linked to science and tech which could be responsible for a new wave of growth worth an extra £14 billion a year to the UK economy by 2025.
Health Secretary Matt Hancock has announced that all opioid medicines in the UK will carry prominent warnings on the labels saying they can cause addiction.
The Department of Health and Social Care today published the 2019 update of their Implementation Plan for England for the UK Strategy for Rare Diseases. This sets out progress made against the original commitments in the Strategy.
A Europe-wide initiative to protect patients and public health from falsified or fake medicines goes live on Saturday 9 February 2019, making the medicines supply chain across Europe safer than ever before.
The Chancellor has announced a £100 million investment for research and technology.
As the UK prepares to leave the EU, the House of Lords is debating a Statutory Instrument which would weaken the UK’s IP framework and damage the country’s reputation as leader in life sciences.
The ABPI has named Elliot Dunster as its Executive Director of Communications.
The Association of the British Pharmaceutical Industry (ABPI) – the trade group representing the branded pharmaceutical industry in the UK – has responded to the outcome of the meaningful vote on the Withdrawal Agreement and Political Deceleration.
The UK Government has launched their National Action Plan to tackle antimicrobial resistance. It sets out how Britain will achieve its new 20-year vision for a world in which AMR is contained and controlled by 2040, covering health, animals, the environment and the food chain.